Lowe Brockenbrough & Co. Inc. Sells 103,314 Shares of Pfizer Inc. (NYSE:PFE)

Lowe Brockenbrough & Co. Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 39.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 158,978 shares of the biopharmaceutical company’s stock after selling 103,314 shares during the period. Lowe Brockenbrough & Co. Inc.’s holdings in Pfizer were worth $4,218,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer during the 4th quarter worth about $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer in the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the 4th quarter valued at about $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $32,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of PFE opened at $26.17 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The firm’s 50 day moving average price is $26.18 and its two-hundred day moving average price is $27.07. The firm has a market cap of $148.29 billion, a P/E ratio of 18.56, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The business’s revenue was up 24.7% on a year-over-year basis. On average, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on PFE shares. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday. Finally, UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.